Home › Research › Treatments
Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease
Christopher Chen, Sadao Katayama, Jae Hong Lee, Jun-Young Lee, Masaki Nakagawa, Kentaro Torii, Tomoo Ogawa, Amitabh Dash et al.. The Journal of Prevention of Alzheimer s Disease, 2025-04-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Of the total of 1795 subjects randomized in Clarity AD, 294 subjects were in the Asian region (Japan:152; Korea:129; Singapore:13). The efficacy of lecanemab was consistent with the overall population. For the primary endpoint, there was a slowing of decline with lecanemab in the CDR-SB at 18 months compared to placebo in the Asian region (adjusted mean difference: -0.349; 95 % confidence intervals: -0.773, 0.076; 24 % slowing of decline). Results for the secondary efficacy endpoints also favored lecanemab versus placebo in Asians. Lecanemab was well tolerated in Asian subjects, with a safety profile in Asian subjects similar to the overall Clarity AD population. The most common adverse events of special interest were ARIA-H (lecanemab:14.4 %; placebo:16.2 %), ARIA-E (lecanemab:6.2 %; placebo:1.4 %), and infusion-related reactions (lecanemab:12.3 %; placebo:1.4 %). Incidence of adverse events leading to study drug dose interruption or withdrawal, infusion-related reactions, ARIA-E and ARIA-H was lower for the lecanemab treated group in the Asian region relative to the overall Clarity AD population. Results from quality of life and biomarker assessments in the Asia region were also generally similar to the overall Clarity AD population. In the Clarity AD Asian region cohort, the overall efficacy, biomarker changes and safety profile of lecanemab were consistent with the overall population, with a favorable risk-benefit profile and manageable risks. ARIA events and infusion-related reactions occurred less commonly with lecanemab in the Asian region subgroup than the overall population.
What this study adds
Evidence grade: High
This is a trial of 294 participants. In the Asian region portion of the phase III Clarity AD trial (294 of 1795 participants), lecanemab slowed decline on the CDR-SB at 18 months compared with placebo, with a safety profile similar to the overall trial population. This supports lecanemab's use in early Alzheimer's disease but does not show it cures or prevents the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chen, C., Katayama, S., Lee, J. H., Lee, J.-Y., Nakagawa, M., Torii, K., et al. (2025). Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2025.100160
Vancouver
Chen C, Katayama S, Lee JH, Lee J.-Y, Nakagawa M, Torii K, et al. Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2025.100160. PMID: 40189473.
BibTeX
@article{chen2025-40189473,
author = {Chen, Christopher and Katayama, Sadao and Lee, Jae Hong and Lee, Jun-Young and Nakagawa, Masaki and Torii, Kentaro and Ogawa, Tomoo and Dash, Amitabh and others},
title = {{Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease}},
journal = {The Journal of Prevention of Alzheimer s Disease},
year = {2025},
doi = {10.1016/j.tjpad.2025.100160},
pmid = {40189473},
url = {https://doi.org/10.1016/j.tjpad.2025.100160}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Of the total of 1795 subjects randomized in Clarity AD, 294 subjects were in the Asian region (Japan:152; Korea:129; Singapore:13).
- The efficacy of lecanemab was consistent with the overall population.
- For the primary endpoint, there was a slowing of decline with lecanemab in the CDR-SB at 18 months compared to placebo in the Asian region (adjusted mean difference: -0.349; 95 % confidence intervals: -0.773, 0.076; 24 % slowing of decline).
- Results for the secondary efficacy endpoints also favored lecanemab versus placebo in Asians.
- Lecanemab was well tolerated in Asian subjects, with a safety profile in Asian subjects similar to the overall Clarity AD population.
Why it matters
In the Asian region portion of the phase III Clarity AD trial (294 of 1795 participants), lecanemab slowed decline on the CDR-SB at 18 months compared with placebo, with a safety profile similar to the overall trial population. This supports lecanemab's use in early Alzheimer's disease but does not show it cures or prevents the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants294
- Evidence strengthHigh
How this study scored 58/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 294 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 45 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 24.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 45 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Takeshi Iwatsubo: h-index 115 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Tokyo: institution h-index 1,463 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40189473) |
| Free to read | 2 / 2 | Free to read |
| Total | 58 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2025.100160
- PubMed: 40189473
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.